Creating a New Way Forward

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.


Laura Chavaree

Patient Engagement

Geoff Eich


Mark Elfers

Finance & Operations

Jen Feng

Senior Product Manager

Lindsay Huffman

Key Account Manager

Rick Lit

Scientific Operations

Michael Malecki

Access & Reimbursement

Michael McKinley

Product Development

Angela Perez

Key Account Manager

George Romanko

Head of HR and Talent

Dianne Shumay, PhD

Clinical Psycho Oncology

Kevin Wyllie

Quality Assurance Engineer

Board of Directors

Geoff Eich

Blue Note Therapeutics

Andrew Firlik, MD

Jazz Venture Partners

John Harris

Jazz Venture Partners

Marcus Neubauer, MD

The US Oncology Network

Board of Advisors

Michael Antoni, PhD

Sylvester Comprehensive Cancer Center

Bio  Research

William Breitbart, MD

Memorial Sloan Kettering Cancer Center

Bio  Research

Patricia Ganz, MD

UCLA Jonsson Comprehensive Cancer Center

Bio  Research

Kevin Knopf, MD

UCSF Institute for Health Policy

Bio  Research

Lidia Schapira, MD

Stanford University Medical Center

Bio  Research

Our Pipeline

Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.

Product Candidate Disease Progression Development Proof of Concept Pivotal Trial FDA Review
BNT001 Early - Mid Stage  
BNT201 Acute In-patient    
BNT301 Late Stage      
BNT401 Survivorship      
Product Candidate Disease Progression Status
BNT001 Early - Mid Stage 2
BNT201 Acute In-patient 1
BNT301 Late Stage 0
BNT401 Survivorship 0
0 = Development
1 = Proof of Concept
2 = Pivotal Trial
3 = FDA Review

We Can't Do This Alone

Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.